Zilico Ltd appoints new Non Executive Director

Wednesday 21st October 2015

Zilico Ltd has appointed Steven Couldwell as a non-executive director to its Board of Directors. 

Mr Couldwell is currently Chief Operating Officer and Head of Global Biosurgery at multinational pharmaceutical company, Sanofi Corporation.

Mr Couldwell was formerly Vice President and General Manager of Covance Laboratories Europe and worked for Smith & Nephew for almost 20 years in a number of roles including President of Orthopaedics (Europe) and Senior VP Sales and Marketing for Smith & Nephew’s Advanced Wound Management business.

The appointment strengthens the healthcare industry expertise of the board and alongside his fellow board members, Mr Couldwell will help provide strategic direction.

ZedScan, Zilico’s flagship product, is a cervical cancer diagnostic system which utilises patented Electrical Impedance Spectroscopy (EIS) technology to improve the ability to detect cervical intraepithelial neoplasia (CIN) following an abnormal smear result, increasing diagnostic accuracy and delivering health economic benefits.

Andrew Newell, Chair of the Board, said: “We are delighted to welcome Steve to Zilico. His outstanding track record in driving business growth in the medical devices sector and will provide invaluable support to the board and executive team.

“Steve joins at an exciting stage in the company’s development. ZedScan is currently being adopted by a number of healthcare markets across the globe and his experience will make a major contribution to the future of Zilico Ltd.”


Editors Notes

For more information about Zilico, please contact:
Zilico, tel: +44 161 826 7840; email: info@zilico.co.uk or visit www.zilico.co.uk

For Press enquiries please contact:
Martin Webb, tel: +44 77 6641 0194; e-mail: martin.webb@propellerpr.org